NasdaqGS - Delayed Quote • USD
Shattuck Labs, Inc. (STTK)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:42 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.45 | -0.43 | -1.73 | -1.78 |
| Low Estimate | -0.52 | -0.5 | -1.85 | -2 |
| High Estimate | -0.38 | -0.38 | -1.56 | -1.56 |
| Year Ago EPS | -0.49 | -0.5 | -2.05 | -1.73 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 2 |
| Avg. Estimate | 230k | 250k | 1.01M | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 710k | 710k | 2.86M | -- |
| Year Ago Sales | 57k | 200k | 1.66M | 1.01M |
| Sales Growth (year/est) | 303.50% | 25.00% | -39.00% | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.63 | -0.52 | -0.52 | -0.57 |
| EPS Actual | -0.49 | -0.5 | -0.65 | -0.41 |
| Difference | 0.14 | 0.02 | -0.13 | 0.16 |
| Surprise % | 22.20% | 3.80% | -25.00% | 28.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.45 | -0.43 | -1.73 | -1.78 |
| 7 Days Ago | -0.45 | -0.43 | -1.73 | -1.78 |
| 30 Days Ago | -0.46 | -0.44 | -1.75 | -1.84 |
| 60 Days Ago | -0.51 | -0.48 | -1.92 | -1.96 |
| 90 Days Ago | -0.51 | -0.48 | -1.92 | -1.96 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | STTK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.20% | -- | -- | 6.50% |
| Next Qtr. | 14.00% | -- | -- | 12.00% |
| Current Year | 15.60% | -- | -- | 5.30% |
| Next Year | -2.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/9/2024 |
| Reiterates | Needham: Buy to Buy | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/13/2024 |
| Reiterates | Needham: Buy to Buy | 2/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Related Tickers
FHTX Foghorn Therapeutics Inc.
5.49
+4.97%
CCCC C4 Therapeutics, Inc.
6.17
-1.12%
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
PRLD Prelude Therapeutics Incorporated
4.0700
+0.74%
ANRO Alto Neuroscience, Inc.
14.18
+0.35%
GYRE Gyre Therapeutics, Inc.
17.11
+4.78%
VIGL Vigil Neuroscience, Inc.
2.7100
+5.04%
NBTX Nanobiotix S.A.
5.74
-1.03%
TRML Tourmaline Bio, Inc.
15.68
-2.00%
STOK Stoke Therapeutics, Inc.
12.41
+6.16%